The Bone Marrow Stem Cell Transplant Program is at the forefront of medicine as it regards the treatment of hematological malignancies and cancers, and performs allogeneic, autologous, and cord transplants. For patients undergoing allogeneic transplant, we offer some innovative and effective approaches such as haplomismatched, non-myeloblative (mini transplants), and donor leukocyte infusion (DLI). After a decade of successfully treating a variety of diseases, the program has gone from being perceived as experimental, to regarded as the standard option for the treatment of certain types of diseases. The program will continue to find new ways to improve the quality of life for cancer patients. Every Faculty Practice Associate in the program is also a staff member of the Mount Sinai Hospital and the Icahn School of Medicine.
Ketamine Shows Significant Benefit in People with Treatment-Resistant Depression
May 20, 2013 - Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic.
Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice
May 17, 2013 - The study, led by James C. Iatridis, PhD, was published in the journal PLOS ONE on May 17.
The Bone Marrow Transplant FPA is open from 9 A.M. to 5 P.M., Monday through Friday.